Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (02315.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

21.4x

Market Cap

HKD 24.24B

MomentumView details →

1D Return

−5.53%

YTD Return

+71.67%

RSI (14)

51.0

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

21.4x

Market Cap

HKD 24.24B

RSI (14)

51.0

MomentumView details →

1D Return

−5.53%

YTD Return

+71.67%

ProfitabilityView details →

Gross Margin

78.05%

Net Margin

17.21%

EBITDA Margin

33.63%

ROE (TTM)

20.45%

ROA (TTM)

13.60%

Asset Turnover

0.78x

GrowthView details →

Revenue YoY

+100.90%

EPS YoY

+161.18%

FCF YoY

+196.78%

Revenue CAGR 3Y

+37.20%

EPS CAGR 3Y

+410.08%

EBITDA YoY

+401.60%

EarningsView details →

EPS (Actual)

HKD 0.62

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.36x

Current Ratio

3.30x

Quick Ratio

2.86x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

2.88B

Net Income (TTM)

495.18M

Op. CF (TTM)

796.17M

Next earningsMar 31, 2027 →

Latest newsMore news →

Biocytogen Pharmaceuticals announced its interim results for the six months ended June 30, 2026, reporting net profit of 241 million RMB, up 402.3% year-on-year, and revenue of 941 million RMB, up 51.6% year-on-year.8d ago

Biocytogen expects net profit attributable to parent for the first half of 2026 to be 236.0944 million to 246.0944 million yuan, up 391.87% to 412.71% year-on-year.29d ago

Similar companies

特宝生物688278.SH Keymed Biosciences Inc.02162.HK 天坛生物600161.SH Roivant Sciences Ltd.ROIV Zai Lab Limited09688.HK Incyte CorporationINCY Find similar companies →

Latest newsMore news →

Biocytogen Pharmaceuticals announced its interim results for the six months ended June 30, 2026, reporting net profit of 241 million RMB, up 402.3% year-on-year, and revenue of 941 million RMB, up 51.6% year-on-year.8d ago Biocytogen expects net profit attributable to parent for the first half of 2026 to be 236.0944 million to 246.0944 million yuan, up 391.87% to 412.71% year-on-year.29d ago Biocytogen-B (2315.HK) shares rose 9.7235% on August 5, 2026, becoming the top gainer among the Hong Kong Commercial Daily*HK Tech Index constituents that day.31d ago